Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook GlobeNewswire January 12, 2026 Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 […]
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance GlobeNewswire January 12, 2026 Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal
New Data Underscoring Ability of Leapfrog Bio's OncoSLX Platform to Identify Drug Retargeting Opportunities for Treating Cancer Published in Nature Portfolio Journal GlobeNewswire January 12, 2026 — Study highlights importance of cancer driver biology in translating results from lab to patients — — Findings validate proprietary OncoSLX Platform(TM), a pharmacogenetic approach that captures the full
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds GlobeNewswire January 12, 2026 DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.(R) (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred
Geron Corporation Provides 2026 Financial Guidance GlobeNewswire January 12, 2026 2026 RYTELO(R) (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY,
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio GlobeNewswire January 12, 2026 New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma GlobeNewswire January 12, 2026 Repeat-doses of DeltEx(TM) Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones GlobeNewswire January 12, 2026 Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation Initial Phase 1 monotherapy data for ERAS-0015 (potential best-in-class pan-RAS molecular
Cabaletta Bio Announces 2026 Strategic Priorities GlobeNewswire January 12, 2026 Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing
Zapata and University of Maryland Collaborate to Advance New Paradigm in Quantum Software Initiative aims to publish a formally verified implementation of Shor's quantum factoring algorithm with relevance to cryptography and other high-value domains GlobeNewswire January 12, 2026 BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — Zapata Quantum, Inc. (OTC: ZPTA) (“Zapata”, “Zapata Quantum” or the